Enzymotec Ltd. Reports Third Quarter 2016 Unaudited Financial Results

Go back to Enzymotec Ltd. Reports Third Quarter 2016 Unaudited Financial Results

Wells Fargo Downgrades Enzymotec (ENZY) to Market Perform

November 17, 2016 6:54 AM EST

Wells Fargo downgraded Enzymotec (NASDAQ: ENZY) from Outperform to Market Perform.

For an analyst ratings summary and ratings history on Enzymotec click here. For more ratings news on Enzymotec click here.

Shares of Enzymotec closed at $5.50 yesterday.

... More

Enzymotec (ENZY) Misses Q3 EPS by 4c; Trims FY16 Outlook; CEO Katz Resigns

November 16, 2016 7:33 AM EST

Enzymotec (NASDAQ: ENZY) reported Q3 EPS of $0.03, $0.04 worse than the analyst estimate of $0.07. Revenue for the quarter came in at $11.4 million versus the consensus estimate of $13.3 million.

CEO Change:

Enzymotec also announced that Dr. Ariel Katz, the Companys President and Chief Executive Officer, will depart the Company by the end of May 2017, and the Board of Directors has initiated a... More